Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific ADC ...
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren ...
MedPage Today on MSN
Recent Developments in Diffuse Large B-Cell Lymphoma
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug ...
Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent pneumococcal conjugate vaccine, Capvaxive, in pediatric and adolescent patients.
In this video, Joshua Brody, MD, discusses primary analysis results from LOTIS-7 and SUNMO trials, both of which are ...
The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...
TAIPEI, Taiwan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-902, an antibody-drug ...
Bristol Myers Squibb is exiting the first U.S.-China pharmaceutical joint venture. Kalexo Bio and Ollin Biosciences have ...
While sentiment in the local biotech sector is improving, a plethora of smaller revenue-generating stocks remain deeply ...
RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback